Literature DB >> 30951946

MicroRNA-384 is lowly expressed in human prostate cancer cells and has anti-tumor functions by acting on HOXB7.

Zhiming Hong1, Wei Fu2, Quan Wang1, Yangling Zeng1, Lijing Qi3.   

Abstract

OBJECTIVES: In this work, we evaluated the expression of microRNA-384 (miR-384) in human prostate cancer (CAP) cells and its regulatory role on CAP in vitro and in vivo functions.
METHODS: In CAP cell lines, miR-384 expression was evaluated by qRT-PCR. In LNCaP and VCaP cells, lentiviral infection was done to overexpress miR-384. The regulatory effects of miR-384 overexpression on CAP in vitro proliferation and migration, and in vivo tumorigenesis, were evaluated, respectively. The targeting of miR-384 on Homeobox b7 gene (HOXB7), was evaluated by dual-luciferase reporter assay and qRT-PCR. In addition, HOXB7 was upregulated in miR-384-overexpressed CAP cells to evaluate the correlated role of HOXB7 in miR-384-mediated CAP proliferation and migration in vitro.
RESULTS: MiR-384 was lowly expressed in CAP cell lines. Lentiviral infection induced miR-384 overexpression inhibited CAP in vitro proliferation and migration, and in vivo tumorigenesis. HOXB7 was directly targeted by miR-384 in CAP cells. In miR-384-overexpressed CAP cells, HOXB7 upregulation reversed the effect of miR-384 by promoting CAP in vitro proliferation and migration.
CONCLUSION: MiR-384 was downregulated in CAP cells. MiR-384 overexpression suppressed CAP in vitro and in vivo development, possibly via acting through its downstream target gene of HOXB7.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  CAP; Cancer function; HOXB7; Migration; Proliferation; Tumorigenesis; miR-384

Mesh:

Substances:

Year:  2019        PMID: 30951946     DOI: 10.1016/j.biopha.2019.108822

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  Oncogenic and tumor-suppressive microRNAs in prostate cancer.

Authors:  Morgan L Zenner; Bethany Baumann; Larisa Nonn
Journal:  Curr Opin Endocr Metab Res       Date:  2020-02-27

2.  Effects of miR-384 and miR-134-5p Acting on YY1 Signaling Transduction on Biological Function of Gastric Cancer Cells.

Authors:  Bing-Zheng Zhong; Qiang Wang; Feng Liu; Jia-Li He; Yi Xiong; Jie Cao
Journal:  Onco Targets Ther       Date:  2020-09-29       Impact factor: 4.147

3.  LncRNA DSCAM-AS1 promotes colorectal cancer progression by acting as a molecular sponge of miR-384 to modulate AKT3 expression.

Authors:  Bo Li; Hai Sun; Jiayu Zhang
Journal:  Aging (Albany NY)       Date:  2020-05-26       Impact factor: 5.682

4.  MiR-384 Inhibits Malignant Biological Behavior Such as Proliferation and Invasion of Osteosarcoma by Regulating IGFBP3.

Authors:  Yuelong Tan; Linlin Chen; Siwei Li; He Hao; Delong Zhang
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

5.  Circular RNA circ_0020123 Promotes Non-Small Cell Lung Cancer Progression Through miR-384/TRIM44 Axis.

Authors:  Qingshan Ma; Baogang Huai; Yuting Liu; Zhongyao Jia; Qilong Zhao
Journal:  Cancer Manag Res       Date:  2021-01-07       Impact factor: 3.989

6.  Luteolin attenuates the chemoresistance of osteosarcoma through inhibiting the PTN/β-catenin/MDR1 signaling axis by upregulating miR-384.

Authors:  Tao Qin; Wenjing Zhu; Xiaoli Kan; Ling Li; Dapeng Wu
Journal:  J Bone Oncol       Date:  2022-04-13       Impact factor: 4.491

Review 7.  RSF1 in cancer: interactions and functions.

Authors:  Guiyang Cai; Qing Yang; Wei Sun
Journal:  Cancer Cell Int       Date:  2021-06-19       Impact factor: 5.722

8.  MicroRNA-939 Directly Targets HDGF to Inhibit the Aggressiveness of Prostate Cancer via Deactivation of the WNT/β-Catenin Pathway.

Authors:  Jie Situ; Hao Zhang; Zi Jin; Ke Li; Yunhua Mao; Wentao Huang
Journal:  Onco Targets Ther       Date:  2020-05-18       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.